Clinical Trial

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

Name: PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma — clinical trial record (NCT07511036)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.

Trial Details

NCT Number	NCT07511036
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Melanoma
Enrollment	20 participants
Start Date	2026-09-01
Primary Completion	2028-05-24 (estimated)
Study Completion	2030-05-24 (estimated)
Updated on ClinicalTrials.gov	2026-04-06